Shareholder Information
Share management and Shareholder Meeting information
2024 Jefferies Global Healthcare Conference
June 5 2024 Download (905KB)Analyst Teach-in
May 23 2024 Download (4.82MB)Q1 2024 Financial Results
April 25 2024 Download (529KB)Annual Report and Accounts 2023
March 13 2024 Download (15.6MB)FY 2023 Financial Results
February 22 2024 Download (628KB)Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac Arrest
June 18 2024Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder
June 10 2024Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance
May 23 2024Indivior Announces Q1 2024 Financial Results
April 25 2024Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone
March 11 2024